News
CYCN
1.680
-1.18%
-0.020
Cyclerion Receives Milestone Payment from Akebia
TipRanks · 4d ago
Weekly Report: what happened at CYCN last week (1124-1128)?
Weekly Report · 5d ago
Weekly Report: what happened at CYCN last week (1117-1121)?
Weekly Report · 11/24 09:02
Weekly Report: what happened at CYCN last week (1110-1114)?
Weekly Report · 11/17 09:02
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 11/11 12:07
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 11/10 21:07
EXCLUSIVE: Cycurion Wins $1 Million+ Contract To Modernize Federal Emergency Warning Network
Benzinga · 11/10 14:16
Weekly Report: what happened at CYCN last week (1103-1107)?
Weekly Report · 11/10 09:02
Weekly Report: what happened at CYCN last week (1027-1031)?
Weekly Report · 11/03 09:02
Weekly Report: what happened at CYCN last week (1020-1024)?
Weekly Report · 10/27 09:02
Weekly Report: what happened at CYCN last week (1013-1017)?
Weekly Report · 10/20 09:02
Weekly Report: what happened at CYCN last week (1006-1010)?
Weekly Report · 10/13 09:02
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 10/06 12:08
Weekly Report: what happened at CYCN last week (0929-1003)?
Weekly Report · 10/06 09:02
Weekly Report: what happened at CYCN last week (0922-0926)?
Weekly Report · 09/29 09:02
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 09/25 17:06
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 09/25 12:08
BUZZ-U.S. STOCKS ON THE MOVE-Marvell, US energy companies, copper miners
Reuters · 09/24 15:52
BUZZ-U.S. STOCKS ON THE MOVE-Thor Industries,  Mirion Technologies, ServiceNow
Reuters · 09/24 13:05
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 09/24 12:10
More
Webull provides a variety of real-time CYCN stock news. You can receive the latest news about Cyclerion Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About CYCN
Cyclerion Therapeutics, Inc. is a biopharmaceutical company dedicated to identifying, developing, and delivering therapies for central nervous system (CNS) diseases. The Company is focused on building a pipeline with therapeutics to treat certain neuropsychiatric diseases. It is focused on an individualized therapy for treatment-resistant depression (TRD) - a condition with significant unmet medical need. Its assets include Olinciguat and Praliciguat. The Company has entered into an exclusive license option agreement for its vascular soluble guanylate cyclase (sGC) stimulator, olinciguat. Praliciguat is an oral, once-daily, systemic sGC stimulator that is licensed to Akeibia Therapeutics, Inc and is being advanced in rare kidney disease.